Speaker illustration

Doctor Joaquin Osca Asensi

University Hospital La Fe, Valencia (Spain)

Member of:

European Society of Cardiology
European Heart Rythm Association

How to assess effective biventricular capture

Event: EHRA 2018

Topic: Cardiac Resynchronization Therapy

Session: Novel approaches to CRT optimisation

Thumbnail

Impact of multipoint pacing in ventricular repolarization; comparison with conventional CRT

Event: EHRA EUROPACE - CARDIOSTIM 2017

Topic: Results (Resynchronization therapy)

Session: Cardiac resynchronisation therapy

Thumbnail

A real-world comparison of visually guided laser balloon ablation and contact force radiofrequency ablation in paroxismal and persistent atrial fibrillation.

Event: EHRA EUROPACE - CARDIOSTIM 2017

Topic: Catheter ablation (Atrial Fibrillation)

Session: Atrial Fibrillation - Catheter ablation

Thumbnail

Association between immediate improvement in left ventricular dyssynchrony and haemodynamics and the long-term response to conventional resynchronization therapy, insights for selecting patien

Event: EHRA EUROPACE - CARDIOSTIM 2017

Topic: Results (Resynchronization therapy)

Session: Cardiac resynchronisation therapy

Thumbnail

Elegibility for subcutaneous defibrillator in high risk patients with tetralogy of fallot

Event: EHRA EUROPACE - CARDIOSTIM 2017

Topic: Technical aspects (Sudden cardiac death and implantable defibrillators)

Session: Sudden cardiac death and implantable defibrillators

Thumbnail

A real-world comparison of vernakalant efficacy and safety for pharmacological cardioversion in patients with recent-onset atrial fibrillation in an emergency department and after cardiac surgery.

Event: EHRA EUROPACE - CARDIOSTIM 2017

Topic: Antiarrhythmic drugs (Atrial Fibrillation)

Session: Atrial Fibrillation - Antiarrhythmic drugs

Thumbnail

Anticoagulation in CHADSVasc1 - Clinical case

Event: ESC CONGRESS 2016

Topic: Atrial fibrillation (AF)

Session: 2016 Atrial fibrillation Guidelines in Spain

Thumbnail

ESC 365 is supported by

logo Novo Nordisk